Sentinel Node Biopsy Market

Increasing incidences of cancer globally to boost the market growth

The Sentinel Node Biopsy (SNB) has been utilized frequently in several cancers, namely breast, melanoma, and the oral cavity among others. The SNB assists the physician in determining if breast cancer or melanoma has spread beyond the original tumor. Sentinel node biopsy is a minimally invasive procedure that helps determine whether cancer has spread to the lymph nodes, providing crucial information for treatment planning. With more cancer cases being diagnosed, the demand for sentinel node biopsy as a reliable staging tool is expected to increase. The increasing prevalence of breast cancer is fueling the demand for sentinel node biopsies.

In February 2023, the World Health Organization reported that approximately 2.3 million cases of breast cancer occur each year, mostly among adults. Furthermore, breast cancer is the first or second leading cause of death in approximately 95% of countries worldwide. Moreover, as per the International Agency for Research on Cancer, there were 325, 000 new diagnosed cases of melanoma globally in 2020. Also, the highest rate has been found in Australia and New Zealand, followed by Western Europe, Northern America, and Northern Europe.

Additionally, there were 377,713 new cases diagnosed with oral cancer worldwide in 2020, and physicians are majorly using SNB for oral cancer for the detection of lymph nodes.

Therefore, increasing incidences of above-mentioned cancer and high demand for SNB for the same are propelling the sentinel node biopsy market's growth.

The Global Sentinel Node Biopsy Market Industry is poised for substantial growth, with projections indicating a market size of 0.72 USD Billion in 2024 and an anticipated increase to 1.15 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 4.4% from 2025 to 2035, reflecting the increasing adoption of sentinel node biopsy in clinical practice. Factors such as technological advancements, rising cancer incidence, and growing awareness among healthcare professionals and patients are likely to contribute to this upward trend. The market's expansion is indicative of the evolving landscape of cancer treatment and the critical role that sentinel node biopsy plays in improving patient outcomes.

The rising incidence of cancer globally is a primary driver for the Global Sentinel Node Biopsy Market Industry. As cancer cases continue to escalate, the demand for effective diagnostic and staging techniques, such as sentinel node biopsy, is likely to increase. For instance, the American Cancer Society reports that in 2024, there will be an estimated 1.9 million new cancer cases diagnosed in the United States alone. This trend is mirrored in various countries, indicating a growing need for innovative surgical techniques that can improve patient outcomes and reduce morbidity. Consequently, the Global Sentinel Node Biopsy Market is projected to reach 0.72 USD Billion in 2024, reflecting the increasing reliance on this procedure in oncological practices.

Growing awareness and education regarding the benefits of sentinel node biopsy are pivotal in driving the Global Sentinel Node Biopsy Market Industry. Healthcare professionals and patients are increasingly informed about the advantages of this procedure in accurately staging cancer and guiding treatment decisions. Educational initiatives by medical associations and institutions have played a crucial role in disseminating knowledge about the procedure's efficacy and safety. This heightened awareness is likely to lead to an increase in the number of procedures performed, thereby contributing to market growth. As a result, the market is projected to experience a compound annual growth rate of 4.4% from 2025 to 2035, reflecting the positive impact of education on patient choices.

Regulatory support and guidelines from health authorities bolster the Global Sentinel Node Biopsy Market Industry. Organizations such as the National Comprehensive Cancer Network provide clear recommendations for the use of sentinel node biopsy in various cancer types, promoting its adoption in clinical practice. These guidelines not only enhance the credibility of the procedure but also encourage healthcare providers to incorporate it into their treatment protocols. As regulatory bodies continue to endorse sentinel node biopsy, the market is likely to benefit from increased utilization rates, further driving growth in the coming years.

The rising demand for minimally invasive procedures is a significant driver of the Global Sentinel Node Biopsy Market Industry. Patients increasingly prefer surgical options that reduce recovery time and minimize complications. Sentinel node biopsy, being less invasive than traditional lymph node dissection, aligns with this trend, offering patients a safer alternative with comparable diagnostic accuracy. This shift in patient preference is evident in various healthcare settings, where surgeons are adopting less invasive techniques to enhance patient satisfaction and outcomes. As the demand for such procedures continues to grow, the market is expected to expand, with an anticipated increase in procedure volumes contributing to overall market growth.

Technological advancements in surgical techniques significantly contribute to the growth of the Global Sentinel Node Biopsy Market Industry. Innovations such as fluorescence imaging and robotic-assisted surgeries enhance the precision and effectiveness of sentinel node biopsies. These technologies not only improve the accuracy of cancer staging but also minimize patient recovery time. For example, the integration of near-infrared fluorescence imaging has shown promising results in identifying sentinel lymph nodes more effectively. As these technologies become more widely adopted, the market is expected to expand, with projections indicating a growth to 1.15 USD Billion by 2035, driven by the increasing adoption of advanced surgical methodologies.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Sentinel Node Biopsy market accounted for the largest market share in 2022due to increasing awareness, technological advancements, and a proactive approach to cancer diagnosis. With a focus on improving patient outcomes, the region's healthcare institutions are embracing sentinel node biopsy procedures, particularly in the context of breast cancer diagnosis. Advanced biopsy systems and technologies like SPY fluorescence imaging are playing a crucial role in enhancing the accuracy and efficiency of these procedures.

The rising incidence of cancer, coupled with the region's commitment to cutting-edge healthcare practices, positions North America at the forefront of the Sentinel Node Biopsy Market, fostering innovation and comprehensive cancer care.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: SENTINEL NODE BIOPSY MARKET BY REGION 2022 & 2032

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Europe Sentinel Node Biopsy market is expected to account for the second-largest market share due to the favorable health policies and trend towards integrating health services, including counseling. Further, the German Sentinel Node Biopsy market was attributed to holding the largest market share, and France Sentinel Node Biopsy market is expected to fastest-growing market in the European region.

The Asia-Pacific healthcare counseling market is expected to grow at the fastest rate from 2024 to 2032. This is due to the rising spending in healthcare, quickly evolving healthcare infrastructure, growing awareness regarding Sentinel Node Biopsy, and growing population in the region. Moreover, China’s Sentinel Node Biopsy market is expected to hold the largest market share, and India Sentinel Node Biopsy market is expected fastest-growing market in the Asia-Pacific region.

The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of Sentinel Node Biopsy in the Middle East and Africa. Increasing awareness and advancements in cancer diagnostic technologies. As healthcare infrastructures continue to develop in the region, there's a rising emphasis on precise cancer staging, positioning sentinel node biopsy as a crucial procedure.

The Sentinel Node Biopsy Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such as BD (US), Stryker (US), Boston Scientific Corporation (US), Hologic, Inc (US), KUB Technologies (US) are dominate the Sentinel Node Biopsy Market due to Type differentiation, financial stability, strategic services, and diversified regional presence. The players are focused on investing in extensive research and development as well.

Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global Sentinel Node Biopsy industry to benefit clients and expand the healthcare counseling market sector is to manufacture locally to reduce operating costs.